MiR •101 and miR •122 Targeting δ‐Catenin to Regulate Keratinocyte Responsiveness to IL ‐ 17A in Psoriasis
The FASEB Journal · 2025
DOI: 10.1096/fj.202500003r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Yingjie Shen und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Huzhou University, Huzhou, P.R. China. Hauptthemen laut MEDLINE: MicroRNAs, Psoriasis, Keratinocytes, Interleukin-17. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Huzhou Natural Science Fund Project, Ningbo Key Laboratory of Skin Science, Ningbo College of Health Sciences.
Abstract (Originalsprache)
Psoriasis is an immune‐mediated inflammatory dermatological disorder characterized by the interaction between immune cells and keratinocytes, which perpetuates cutaneous inflammation and cellular hyperproliferation. In this study, we identified a strong δ‐catenin signature in psoriatic skin; however, the precise role of δ‐catenin remains to be elucidated. Additionally, we observed that Interleukin (IL)‐17A, a pivotal cytokine involved in the development of psoriatic lesions, induces δ‐catenin expression in HEKn and HACAT cells. From a mechanistic perspective, δ‐catenin initiated NF‐κB signaling, subsequently leading to the activation of IL‐6 and IL‐8 production. Furthermore, silencing δ‐catenin expression mitigated IL‐17A‐induced hyperproliferation of keratinocytes through the NF‐κB pathway. Our study further identified miR‐101 and miR‐122 as upstream regulators of δ‐catenin, exerting their effects by downregulating δ‐catenin protein levels. We demonstrated that miR‐101 and miR‐122 can inhibit the hyperproliferation of keratinocytes induced by δ‐catenin. These findings validate the role of δ‐catenin in the pathogenesis of psoriasis, particularly in keratinocyte‐mediated inflammatory responses and cellular hyperproliferation. Consequently, miR‐101 and miR‐122 hold potential as therapeutic agents in the treatment of psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Huzhou University, Huzhou, P.R. China.
- Ningbo Key Laboratory of Skin Science, Ningbo College of Health Sciences, Ningbo, P.R. China.
- Pharmacy Department, Wenzhou Central Hospital, Wenzhou, P.R. China.
ORCID-Profile: Yingjie Shen, Yitong Zhou, Kuziwakwashe Alice Chiwa, Junxin Wang, Shihong Ren, Mingxuan Wang, Hongru Ren, Yeyi Zheng, Ying Yu, Lutao Jiang, Jingmou Yu, Yuchun Qiao, Litai Jin, Jianlin Lou, Xiangkuo Zheng
Förderung
- National Natural Science Foundation of China
- Huzhou Natural Science Fund Project
- Ningbo Key Laboratory of Skin Science, Ningbo College of Health Sciences
Zitieren
APA
Shen, Y., Zhou, Y., Chiwa, K. A., Wang, J., Ren, S., Wang, M., Ren, H., Zheng, Y., Yu, Y., Jiang, L., Yu, J., Qiao, Y., Jin, L., Lou, J., & Zheng, X. (2025). MiR •101 and miR •122 Targeting δ‐Catenin to Regulate Keratinocyte Responsiveness to IL ‐ 17A in Psoriasis. The FASEB Journal. https://doi.org/10.1096/fj.202500003r
Vancouver
Shen Y, Zhou Y, Chiwa KA, Wang J, Ren S, Wang M, et al. MiR •101 and miR •122 Targeting δ‐Catenin to Regulate Keratinocyte Responsiveness to IL ‐ 17A in Psoriasis. The FASEB Journal. 2025. doi:10.1096/fj.202500003r
BibTeX
@article{Shen2025,
author = {Shen, Yingjie and Zhou, Yitong and Chiwa, Kuziwakwashe Alice and Wang, Junxin and Ren, Shihong and Wang, Mingxuan and Ren, Hongru and Zheng, Yeyi and Yu, Ying and Jiang, Lutao and Yu, Jingmou and Qiao, Yuchun and Jin, Litai and Lou, Jianlin and Zheng, Xiangkuo},
title = {MiR •101 and miR •122 Targeting δ‐Catenin to Regulate Keratinocyte Responsiveness to IL ‐ 17A in Psoriasis},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202500003r}
}
EUVIMED